Bellerophon Stock Analysis

BLPH -  USA Stock  

USD 2.53  0.08  3.27%

The current drop in stock price could raise concerns from stockholders as the firm it trading at a share price of 2.53 on 46,431 in volume. The company directors and management have failed to build on market volatilities in December. However, diversifying your overall positions with Bellerophon Ther Com may protect your principal portfolio during upcoming market swings. The stock standard deviation of daily returns for 90 days investing horizon is currently 6.58. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Bellerophon Ther partners.
Continue to Trending Equities.

Bellerophon Stock Analysis 

 
Refresh
The Bellerophon Ther stock analysis report makes it easy to digest most publicly released information about Bellerophon Ther and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Bellerophon Stock analysis module also helps to analyze the Bellerophon Ther price relationship with some important fundamental indicators such as market cap and management efficiency.

Bellerophon Stock Analysis Notes

About 32.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.93. Some equities with similar Price to Book (P/B) outperform the market in the long run. Bellerophon Ther Com recorded a loss per share of 2.26. The entity had not issued any dividends in recent years. The firm had 1-15 split on the 10th of February 2020. Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey. Bellerophon Ther operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 21 people. For more info on Bellerophon Ther Com please contact Jonathan Peacock at 908 574 4770 or go to https://www.bellerophon.com.

Bellerophon Ther Com Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Bellerophon Ther's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Bellerophon Ther Com or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Bellerophon Ther Com generated a negative expected return over the last 90 days
Bellerophon Ther Com has high historical volatility and very poor performance
Net Loss for the year was (21.49 M) with profit before overhead, payroll, taxes, and interest of 0.
Bellerophon Ther Com currently holds about 28.71 M in cash with (25.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Bellerophon Ther Com has a very weak financial position based on the latest SEC disclosures
Latest headline from MacroaxisInsider: Acquisition by Teufel Crispin of 21828 shares of Bellerophon Ther subject to Rule 16b-3

Bellerophon Ther Com Upcoming and Recent Events

Earnings reports are used by Bellerophon Ther to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Bellerophon Ther previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report10th of March 2022
Next Earnings Report10th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End10th of March 2022
Last Quarter Report30th of September 2021
Last Earning Announcement31st of December 2020

Bellerophon Largest EPS Surprises

Earnings surprises can significantly impact Bellerophon Ther's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-05-11
2021-03-31-0.71-0.580.1318 
2021-11-15
2021-09-30-0.63-0.490.1422 
2015-08-13
2015-06-30-1.08-0.90.1816 
View All Earnings Estimates

Bellerophon Ther SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Bellerophon Ther prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Bellerophon Ther investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Bellerophon Ther Com specific information freely available to individual and institutional investors to make a timely investment decision.
5th of January 2022
Financial Statements and Exhibits. Regulation FD Disclosure
View
4th of January 2022
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
17th of December 2021
Financial Statements and Exhibits. Other Events
View
15th of November 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
12th of November 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
12th of October 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
6th of October 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
31st of August 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View

Bellerophon Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 24.05 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Bellerophon Ther's market, we take the total number of its shares issued and multiply it by Bellerophon Ther's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Bellerophon Profitablity

Bellerophon Ther's profitability indicators refer to fundamental financial ratios that showcase Bellerophon Ther's ability to generate income relative to its revenue or operating costs. If, let's say, Bellerophon Ther is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Bellerophon Ther's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Bellerophon Ther's profitability requires more research than a typical breakdown of Bellerophon Ther's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Average Assets(0.63) (0.68) 
Return on Average Equity(0.81) (0.87) 
Return on Invested Capital 9.17  9.89 

Management Efficiency

The entity has return on total asset (ROA) of (29.75) % which means that it has lost $29.75 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (59.97) %, meaning that it created substantial loss on money invested by shareholders. Bellerophon Ther management efficiency ratios could be used to measure how well bellerophon ther com manages its routine affairs as well as how well it operates its assets and liabilities. The current Return on Invested Capital is estimated to increase to 9.89, while Return on Average Assets are projected to decrease to (0.68) . Bellerophon Ther Tangible Assets Book Value per Share are most likely to decrease significantly in the upcoming years. The last year's value of Tangible Assets Book Value per Share was reported at 5.80
Last ReportedProjected for 2022
Book Value per Share 4.42  4.53 
Enterprise Value over EBIT(1.15) (1.24) 
Enterprise Value over EBITDA(0.37) (0.40) 
Price to Book Value 1.90  2.05 
Tangible Assets Book Value per Share 5.80  5.95 
Enterprise Value10 M10.3 M
Tangible Asset Value57.8 M46.6 M

Technical Drivers

As of the 26th of January, Bellerophon Ther shows the risk adjusted performance of (0.06), and Mean Deviation of 4.01. Bellerophon Ther Com technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Bellerophon Ther Com, which can be compared to its rivals. Please confirm Bellerophon Ther Com information ratio, as well as the relationship between the value at risk and expected short fall to decide if Bellerophon Ther Com is priced correctly, providing market reflects its regular price of 2.53 per share. Please also double-check Bellerophon Ther Com total risk alpha, which is currently at (0.046532) to validate the company can sustain itself at a future point.

Bellerophon Ther Com Price Movement Analysis

The output start index for this execution was one with a total number of output elements of sixty. The Simple Moving Average indicator is calculated by adding the closing price of Bellerophon Ther for a given number of time periods and then dividing this total by the number of time periods. It is used to smooth out Bellerophon Ther Com short-term fluctuations and highlight longer-term trends or cycles. View also all equity analysis or get more info about simple moving average overlap studies indicator.

Bellerophon Ther Com Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bellerophon Ther insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bellerophon Ther's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bellerophon Ther insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Teufel Crispin over two weeks ago via Macroaxis 
Acquisition by Teufel Crispin of 21828 shares of Bellerophon Ther subject to Rule 16b-3
Laccona Nicholas over three months ago via Macroaxis 
Bellerophon Ther exotic insider transaction detected
Puissance Life Science Opportunities Fund Vi over three months ago via Macroaxis 
Acquisition by Puissance Life Science Opportunities Fund Vi of 8189 shares of Bellerophon Ther subject to Rule 16b-3
Puissance Life Science Opportunities Fund Vi over six months ago via Macroaxis 
Acquisition by Puissance Life Science Opportunities Fund Vi of 8189 shares of Bellerophon Ther subject to Rule 16b-3
Puissance Life Science Opportunities Fund Vi over six months ago via Macroaxis 
Acquisition by Puissance Life Science Opportunities Fund Vi of 304286 shares of Bellerophon Ther subject to Rule 16b-3
Jonathan Peacock over six months ago via Macroaxis 
Acquisition by Jonathan Peacock of 15308 shares of Bellerophon Ther subject to Rule 16b-3
New Mountain Investments Ii Llc over six months ago via Macroaxis 
Sale by New Mountain Investments Ii Llc of 400000 shares of Bellerophon Ther
Fares Wassim over a year ago via Macroaxis 
Acquisition by Fares Wassim of 30000 shares of Bellerophon Therapeutics subject to Rule 16b-3
Edmonds Amy over a year ago via Macroaxis 
Acquisition by Edmonds Amy of 56411 shares of Bellerophon Therapeutics subject to Rule 16b-3
Theodore Wang over a year ago via Macroaxis 
Purchase by Theodore Wang of 2600 shares of Bellerophon Therapeutics
Puissance Life Science Opportunities Fund Vi over a year ago via Macroaxis 
Acquisition by Puissance Life Science Opportunities Fund Vi of 1153846 shares of Bellerophon Therapeutics subject to Rule 16b-3
Jonathan Peacock over a year ago via Macroaxis 
Purchase by Jonathan Peacock of 7500 shares of Bellerophon Therapeutics

Bellerophon Ther Technical and Predictive Indicators

Bellerophon Ther Forecast Models

Bellerophon Ther time-series forecasting models is one of many Bellerophon Ther's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Bellerophon Ther's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Bellerophon Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Bellerophon Ther stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Bellerophon shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Bellerophon Ther. By using and applying Bellerophon Stock analysis, traders can create a robust methodology for identifying Bellerophon entry and exit points for their positions.
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey. Bellerophon Ther operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 21 people.

Current Bellerophon Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Bellerophon analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Bellerophon analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
25.0Strong Buy3Odds
Bellerophon Ther Com current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Bellerophon analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Bellerophon stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Bellerophon Ther Com, talking to its executives and customers, or listening to Bellerophon conference calls.
Bellerophon Analyst Advice Details

Bellerophon Stock Analysis Indicators

Bellerophon Ther Com stock analysis indicators help investors evaluate how Bellerophon Ther stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Bellerophon Ther shares will generate the highest return on investment. By understating and applying Bellerophon Ther stock analysis, traders can identify Bellerophon Ther position entry and exit signals to maximize returns.
Quick Ratio5.60
Fifty Two Week Low2.3400
Shares Short Prior Month51.98k
Average Daily Volume Last 10 Day88.91k
Average Daily Volume In Three Month907.69k
Shares Percent Shares Out0.45%
Short Percent Of Float0.54%
Forward Price Earnings-1.07
Float Shares6.95M
Fifty Two Week High9.1850
Enterprise Value To Ebitda-0.09
Fifty Day Average2.9824
Two Hundred Day Average3.8862
Continue to Trending Equities. Note that the Bellerophon Ther Com information on this page should be used as a complementary analysis to other Bellerophon Ther's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Complementary Tools for Bellerophon Stock analysis

When running Bellerophon Ther Com price analysis, check to measure Bellerophon Ther's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bellerophon Ther is operating at the current time. Most of Bellerophon Ther's value examination focuses on studying past and present price action to predict the probability of Bellerophon Ther's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Bellerophon Ther's price. Additionally, you may evaluate how the addition of Bellerophon Ther to your portfolios can decrease your overall portfolio volatility.
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Is Bellerophon Ther's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bellerophon Ther. If investors know Bellerophon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bellerophon Ther listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Bellerophon Ther Com is measured differently than its book value, which is the value of Bellerophon that is recorded on the company's balance sheet. Investors also form their own opinion of Bellerophon Ther's value that differs from its market value or its book value, called intrinsic value, which is Bellerophon Ther's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bellerophon Ther's market value can be influenced by many factors that don't directly affect Bellerophon Ther's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bellerophon Ther's value and its price as these two are different measures arrived at by different means. Investors typically determine Bellerophon Ther value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bellerophon Ther's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.